FDA Approvals Roundup: StrataGraft, Rezipres, Trikafta | RAPS
Rare diseases top another strong year for novel drug approvals | Evaluate
Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment | Scientific Reports
HSE agrees to reimburse cost of new cystic fibrosis treatment
Vertex's Trikafta gets FDA approval to treat cystic fibrosis in children - Pharmaceutical Technology
FDA approves Trikafta for children aged 6 to 11 with cystic fibrosis
Health Canada OKs Kalydeco Label Expansion for Toddlers Age 1-2
Vertex Updates Warnings Section of Trikafta Label
FDA Expands Vertex CFTR Modulators Labels for More CF Mutations
Vertex (VRTX) Symkevi/Kalydeco Label Expansion Gets EU Nod
Cystic Fibrosis Time Traveling Thanks to Trikafta
Trikafta - FDA prescribing information, side effects and uses
Vertex Announces FDA Approvals of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for Use in People With CF With Certain Rare Mutations | Business Wire
KaftrioNOW: The Buzz Tag For Cystic Fibrosis That Is Trending On Social Media | by Emma Boniface | Coughy and Creon | Medium
What competition? Vertex touts Trikafta's competitive edge on back of strong 2021 | FiercePharma
Trikafta - FDA prescribing information, side effects and uses
Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study - The Lancet
Downloadable Materials | TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor)
JP Morgan 2022 – Abbvie looks to crack the cystic fibrosis code | Evaluate
Document
Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study - The Lancet
FDA Approves Trikafta to Treat CF in Children Starting at Age 6
Trikafta - FDA prescribing information, side effects and uses
Trikafta - FDA prescribing information, side effects and uses
NHS spent £100million on deal with a US pharmaceutical firm for the wrong cystic fibrosis drug | Daily Mail Online
Study: CF Medication Trikafta Safe and Effective for Children Ages 6–11
